Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer
UNICANCER · Locations not reported · Updated 2026-08-04
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Elevar Therapeutics · 19 locations · Updated 2026-11-09
HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)
Oslo University Hospital · 1 locations · Updated 2026-02-02
Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Medigen Biotechnology Corporation · 1 locations · Updated 2025-12-17
Bile ctDNA Genomic Profiling and Concordance With Tumor Tissue in Biliary Tract Cancer
CHA University · 1 locations · Updated 2026-10-13
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital · 1 locations · Updated 2026-09-23
Prognostic Evaluation and Systematic Re-Assessment of Cholangiocarcinoma Therapy
Karolinska University Hospital · Locations not reported · Updated 2026-09-11
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
University of California, Irvine · 1 locations · Updated 2026-08-31
On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer
Region Skane · 3 locations · Updated 2026-08-03
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Mayo Clinic · 1 locations · Updated 2026-05-13
LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)
Azienda Sanitaria Ospedaliera · 1 locations · Updated 2026-04-03
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
CHA University · 1 locations · Updated 2026-03-18
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University · 1 locations · Updated 2026-03-18
Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
CHA University · 1 locations · Updated 2026-03-18
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Aarhus University Hospital · 1 locations · Updated 2026-03-06
Use of Ctdna in Patients With Gastrointestinal Tract Tumors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 locations · Updated 2025-09-02
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
Second Affiliated Hospital, Zhejiang University, School of Medicine · 1 locations · Updated 2025-02-10
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance
Tongji Hospital · 1 locations · Updated 2024-12-30
LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)
Azienda Sanitaria Ospedaliera · 1 locations · Updated 2024-01-24
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.